{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:45:40Z","timestamp":1791229540986,"version":"4.1.0"},"reference-count":17,"publisher":"Informa UK Limited","issue":"3","license":[{"start":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T00:00:00Z","timestamp":1736899200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Merck Sharp & Dohme LLC"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncology"],"published-print":{"date-parts":[[2025,1,26]]},"DOI":"10.1080\/14796694.2024.2444874","type":"journal-article","created":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T08:48:51Z","timestamp":1736930931000},"page":"313-319","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":5,"title":["Prevalence of medical conditions or comorbidities influencing first-line therapy in unresectable hepatocellular carcinoma in the United States"],"prefix":"10.1080","volume":"21","author":[{"given":"Tammy A.","family":"Schuler","sequence":"first","affiliation":[{"name":"Cardinal Health","place":["Dublin, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shital","family":"Kamble","sequence":"additional","affiliation":[{"name":"Merck & Co. Inc","place":["Rahway, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaushal","family":"Desai","sequence":"additional","affiliation":[{"name":"Merck & Co. Inc","place":["Rahway, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Bland","sequence":"additional","affiliation":[{"name":"Cardinal Health","place":["Dublin, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonid","family":"Dubrovsky","sequence":"additional","affiliation":[{"name":"Merck & Co. Inc","place":["Rahway, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Feinberg","sequence":"additional","affiliation":[{"name":"Cardinal Health","place":["Dublin, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,1,15]]},"reference":[{"key":"e_1_3_8_3_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21492"},{"key":"e_1_3_8_4_1","unstructured":"Cancer stat facts: liver and intrahepatic bile duct cancer [cited 2024 Oct 21]. Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/livibd.html#"},{"issue":"1","key":"e_1_3_8_5_1","first-page":"1","article-title":"Updates on systemic therapy for hepatocellular carcinoma","volume":"44","author":"Ntellas P","year":"2024","unstructured":"Ntellas P, Chau I. Updates on systemic therapy for hepatocellular carcinoma. ASCO Educational Book. 2024;44(1):1.","journal-title":"ASCO Educational Book"},{"key":"e_1_3_8_6_1","unstructured":"National Cancer Institute. Atezolizumab plus bevacizumab approved to treat liver cancer [cited 2024 Oct 21]. Available from: https:\/\/www.cancer.gov\/news-events\/cancer-currents-blog\/2020\/fda-atezolizumab-bevacizumab-liver-cancer"},{"key":"e_1_3_8_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1915745"},{"key":"e_1_3_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.11.030"},{"key":"e_1_3_8_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2100070"},{"key":"e_1_3_8_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.02.005"},{"key":"e_1_3_8_11_1","unstructured":"National Comprehensive Cancer Network. Treatment by cancer type. NCCN guidelines. Hepatocellular carcinoma version 3. 2024 [updated 2024; accessed 2024 Oct 21]. Available from: https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1514"},{"key":"e_1_3_8_12_1","unstructured":"Food and Drug Administration. Full prescribing information TECENTRIQ [cited 2020 May; accessed 2024 Oct 21]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/761034s025lbl.pdf"},{"key":"e_1_3_8_13_1","unstructured":"Food and Drug Administration. Full prescribing information AVASTIN [cited 2020 May; accessed 2024 Oct 21]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/125085s332lbl.pdf"},{"issue":"4","key":"e_1_3_8_14_1","first-page":"476","article-title":"Real-world treatment patterns, clinical outcomes, and health care resource utilization in advanced unresectable hepatocellular carcinoma","volume":"5","author":"O\u2019Sullivan DE","year":"2022","unstructured":"O\u2019Sullivan DE, Boyne DJ, Syed IA, et al. Real-world treatment patterns, clinical outcomes, and health care resource utilization in advanced unresectable hepatocellular carcinoma. Can Liver J. 2022;5(4):476.","journal-title":"Can Liver J"},{"key":"e_1_3_8_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.3_suppl.445"},{"key":"e_1_3_8_16_1","doi-asserted-by":"publisher","DOI":"10.1159\/000525582"},{"key":"e_1_3_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2022.07.003"},{"key":"e_1_3_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2022.08.024"},{"key":"e_1_3_8_19_1","doi-asserted-by":"publisher","DOI":"10.1159\/000514312"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14796694.2024.2444874","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:03:39Z","timestamp":1738368219000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14796694.2024.2444874"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,15]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,1,26]]}},"alternative-id":["10.1080\/14796694.2024.2444874"],"URL":"https:\/\/doi.org\/10.1080\/14796694.2024.2444874","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,15]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-04-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}